The prevalence of H. pylori is still substantial in rheumatic patients

Scandinavian Journal of Rheumatology

Volumn 31, Issue 2, 2002, Pages 94-96

  De Leest, H T J I ^a   Steen, K S S ^a   Van Wijngaarden, S ^a   Lems, W F ^a   Van Der Laar, M A F J ^a   Dijkmans, B A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Helicobacter pylori; NSAID; Prevalence; Rheumatic diseases

Indexed keywords

IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIBODY TITER; ARTICLE; BACTERIUM DETECTION; BLOOD SAMPLING; GASTROINTESTINAL MUCOSA; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; PATHOGENESIS; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROPREVALENCE; UPPER GASTROINTESTINAL TRACT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, BACTERIAL; COHORT STUDIES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RHEUMATIC DISEASES; SEROEPIDEMIOLOGIC STUDIES;

EID: 0036097701     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740252937612     Document Type: Article

References (17)

1. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
2. Helicobacter pylori and the risk and management of associated diseases: Gastritis, ulcer disease, atrophic gastritis and gastric cancer
3. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report
4. Does Helicobacter pylori status affect nonsteroidal anti-inflammatory drug-associated gastroduodenal pathology?
5. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
6. Nonsteroidal anti-inflammatory drug gastropathy and helicobacter pylori: The search for an improbable consensus
7. Helicobacter pylori and the birth cohort effect: Evidence of a continuous decrease of infection rates in childhood
8. Evaluation of eight enzyme immunoassays for detection of immunoglobulin G against Helicobacter pylori
9. An investigation into factors associated with Helicobacter pylori infection
10. Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations
11. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons
12. The prevalence of anti-Helicobacter (Campylobacter) pylori antibodies in patients and healthy blood donors
13. Long-term omeprazole therapy does not affect Helicobacter pylori status in most patients
14. No effect of intramuscular gold therapy on serological parameters of Helicobacter pylori infection in patients with rheumatoid arthritis: A 12 month prospective study
15. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs
16. Serum values of pepsinogens and antibodies to Helicobacter pylori in relation to a history of peptic ulcer disease and NSAID use
17. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis